UKRI Translation: MRC Impact Acceleration Awards support academic teams to test one high-risk step in medical intervention development, generating evidence to guide onward development or patient benefit.
The application window changed from 16 July–11 November 2026 to 12 November 2026–10 March 2027. For applications submitted after 1 April 2026, the uninvited-resubmission ban now covers previous submissions to MRC or other UKRI funders, rather than any funder; the application link and eligibility guidance also changed.
Funder: UK Research and Innovation
Due Dates: March 10, 2027, 4:00pm UK time (Closing date)
Funding Amounts: £50,000–£300,000 full economic cost for six to 18 months; 80% funded, plus 100% of permitted exceptions
Summary: Supports one high-risk development step generating critical evidence for a medical intervention’s onward development or patient benefit.
Key Information: Only one application per project lead; projects must address a single evidence gap, not multiple work packages.
The Medical Research Council (MRC), part of UKRI, supports academically led translational projects developing new or repurposed medicines, devices, diagnostics and other medical interventions. Formerly the Gap Fund, this award bridges Impact Acceleration Accounts (IAAs) and larger MRC Proof of Concept awards. It funds critical data that can reduce development uncertainty—or establish that an approach should not progress.
The scope covers all human diseases in UK healthcare and global health contexts. Priorities include precision prevention, earlier diagnosis, advanced treatments, outcome monitoring and improved disease management. Supported interventions include small molecules, vaccines, biologics, advanced and complex therapeutics, regenerative medicine, digital healthcare, imaging, surgical tools, behavioural interventions and radiotherapy. Examples of work include prototype testing, biomarker validation, vector optimisation and high-risk therapeutic discovery linked to product development.